Author

Ira Jacobs

Observed names: I Jacobs, I. Jacobs, Ira A. Jacobs, Ira Allen Jacobs, Jacobs, Ira

Observed institutions: Amgen (United States), Pfizer (United States), Morristown Medical Center, University of Illinois Chicago

ORCID: 0000-0001-8350-7760

Observed ORCID: 0000-0001-8350-7760

OpenAlex ID: A5102822011

Drug tendering: drug supply and shortage implications for the uptake of biosimilars

2017 · George Dranitsaris, Ira Jacobs, et al. · ClinicoEconomics and Outcomes Research · 67

PDF

2014 · Katherine H. Rak Tkaczuk, Ira Allen Jacobs · Seminars in Oncology · 59

PDF

Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone

2018 · Jacob Engellau, Leanne Seeger, et al. · World Journal of Surgical Oncology · 58

PDF

Global Acceptance of Biosimilars: Importance of Regulatory Consistency, Education, and Trust

2018 · Eduardo Cazap, Ira Jacobs, et al. · The Oncologist · 49

PDF

Development of biosimilars in an era of oncologic drug shortages

2015 · Edward Li, Janakiraman Subramanian, et al. · Drug Design Development and Therapy · 42

PDF

Nonoperative Management of Blunt Splenic and Hepatic Trauma in the Pediatric Population: Significant Differences between Adult and Pediatric Surgeons?

2001 · Ira A. Jacobs, Kathleen Kelly, et al. · The American Surgeon · 39

2017 · Ralph Boccia, Ira Jacobs, et al. · Cancer Management and Research · 19

PDF

Accelerating Virtual Health Implementation Following the COVID-19 Pandemic: Questionnaire Study

2022 · Melissa Stahl, James Cheung, et al. · JMIR Formative Research · 18

Metastatic Infiltrating Syringomatous Adenoma of the Breast

2003 · C. K. Chang, Ira A. Jacobs, et al. · Archives of Pathology & Laboratory Medicine · 18

Functional Outcomes and Quality of Life for Patients With Cachexia and Solid Tumour Cancers: Findings of a Systematic Literature Review

2026 · Jeffrey Crawford, Marie Fallon, et al. · Journal of Cachexia Sarcopenia and Muscle · 1

Defining Cachexia in Children With Cancer in the United States: Developing a Framework to Inform Clinical and Research Practice

2026 · Daniel V. Runco, Guohai Zhou, et al. · Journal of Human Nutrition and Dietetics

PDF

Supplementary Figure 1 from Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone

2023 · Daniel G. Branstetter, Scott D. Nelson, et al.

Supplementary Figure Legend from Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone

2023 · Daniel G. Branstetter, Scott D. Nelson, et al.

PDF

Data from Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone

2023 · Daniel G. Branstetter, Scott D. Nelson, et al.

Data from Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone

2023 · Daniel G. Branstetter, Scott D. Nelson, et al.

EPH139 Deprivation and Access to Care Among Patients With Melanoma in the UK

2022 · C Quinn, M Larkin, et al. · Value in Health

Denosumab decreases proliferation in giant cell tumor of bone (GCTB)

2010 · M. Roudier, J.Y. Blay*, et al. · Bone

Works count: 19

Citation count: 370

H-index: 9

I10-index: 9